{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:16:04Z","timestamp":1788250564962,"version":"build-2803163510"},"reference-count":50,"publisher":"Portland Press Ltd.","issue":"10","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5,1]]},"abstract":"<jats:p>PCOS (polycystic ovary syndrome) is associated with reproductive abnormalities, IR (insulin resistance) and elevated risk factors for CVD (cardiovascular disease) and Type\u00a02 diabetes, including endothelial dysfunction. The present study aimed to assess a range of circulating markers of endothelial function in overweight women with and without PCOS. Overweight and obese age- and BMI (body mass index)-matched women with (n=80) and without (n=27) PCOS were assessed in a cross-sectional study. End-point measures were HOMA (homoeostasis model assessment)-IR, androgens, lipids, inflammatory markers [hsCRP (high-sensitivity C-reactive protein)] and endothelial function [FMD (flow-mediated dilation), ADMA (asymmetric dimethylarginine), PAI-1 (plasminogen activator inhibitor-1) and vWF (von Willebrand factor)]. Women with PCOS had elevated HOMA-IR (4.1\u00b13.4 compared with 1.9\u00b11.4), free androgen index (9.3\u00b15.6 compared with 4.6\u00b13.8), total cholesterol (5.2\u00b11.0 compared with 4.7\u00b10.9\u00a0mmol\/l) and triacylglycerols (triglycerides; 1.4\u00b10.7 compared with 0.9\u00b10.3\u00a0mmol\/l) (P&amp;lt;0.05 for all), but similar hsCRP compared with women without PCOS. With regard to endothelial function, women with PCOS had elevated ADMA (1.0\u00b10.4 compared 0.3\u00b10.1\u00a0\u03bcmol\/l, P&amp;lt;0.001) and PAI-1 (5.6\u00b11.8 compared with 4.6\u00b11.1\u00a0units\/ml, P=0.006), a trend towards worsened FMD (11.8\u00b15.0 compared with 13.5\u00b14.0%, P=0.075) and no difference in vWF compared with controls. For all subjects, ADMA (P=0.002) and PAI-1 (P&amp;lt;0.001) were increased with higher tertiles of HOMA-IR. Women with PCOS are hyperandrogenic, dyslipidaemic and have IR, and have risk factors for CVD and diabetes including increased circulating markers of endothelial function (ADMA and PAI-1) and a trend towards worse FMD as a global marker of endothelial function. In PCOS, deterioration in endothelial function is related to IR, hyperandrogenism and other factors.<\/jats:p>","DOI":"10.1042\/cs20080218","type":"journal-article","created":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T08:58:50Z","timestamp":1224147530000},"page":"761-770","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome"],"prefix":"10.1042","volume":"116","author":[{"given":"Lisa\u00a0J.","family":"Moran","sequence":"first","affiliation":[{"name":"The Jean Hailes Foundation for Women's Health, Monash Institute of Health Services Research, Monash University, Melbourne 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha\u00a0K.","family":"Hutchison","sequence":"additional","affiliation":[{"name":"The Jean Hailes Foundation for Women's Health, Monash Institute of Health Services Research, Monash University, Melbourne 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Meyer","sequence":"additional","affiliation":[{"name":"Diabetes Unit, Southern Health, Melbourne 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[{"name":"The Jean Hailes Foundation for Women's Health, Monash Institute of Health Services Research, Monash University, Melbourne 3168, Australia"},{"name":"Diabetes Unit, Southern Health, Melbourne 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena\u00a0J.","family":"Teede","sequence":"additional","affiliation":[{"name":"The Jean Hailes Foundation for Women's Health, Monash Institute of Health Services Research, Monash University, Melbourne 3168, Australia"},{"name":"Diabetes Unit, Southern Health, Melbourne 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2009,4,15]]},"reference":[{"key":"2021113010064600900_B1","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1210\/jc.2004-1487","article-title":"Vascular dysfunction and metabolic parameters in polycystic ovary syndrome","volume":"90","author":"Meyer","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B2","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1210\/jc.2005-0011","article-title":"Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease","volume":"90","author":"Meyer","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1530\/eje.1.01910","article-title":"Metformin administration improves endothelial function in women with polycystic ovary syndrome","volume":"152","author":"Diamanti-Kandarakis","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"2021113010064600900_B4","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1210\/jc.2003-031867","article-title":"Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome","volume":"89","author":"Orio","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2362.2006.01712.x","article-title":"Inflammatory and endothelial markers in women with polycystic ovary syndrome","volume":"36","author":"Diamanti-Kandarakis","year":"2006","journal-title":"Eur. J. Clin. Invest."},{"key":"2021113010064600900_B6","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1210\/jc.2003-032237","article-title":"Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome","volume":"89","author":"Talbott","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/humrep\/16.9.1995","article-title":"Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome","volume":"16","author":"Norman","year":"2001","journal-title":"Hum. Reprod."},{"key":"2021113010064600900_B8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2796.2007.01830.x","article-title":"Endothelial dysfunction in insulin resistance and type\u00a02 diabetes","volume":"262","author":"Jansson","year":"2007","journal-title":"J. Int. Med."},{"key":"2021113010064600900_B9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/07853890500472151","article-title":"Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond","volume":"38","author":"Boger","year":"2006","journal-title":"Ann. Med."},{"key":"2021113010064600900_B10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00277-006-0085-5","article-title":"Von Willebrand factor and thrombosis","volume":"85","author":"Franchini","year":"2006","journal-title":"Ann. Hematol."},{"key":"2021113010064600900_B11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2337\/diacare.28.3.702","article-title":"Endothelial-dependent vasodilation and incidence of type\u00a02 diabetes in a population of healthy postmenopausal women","volume":"28","author":"Rossi","year":"2005","journal-title":"Diabetes Care"},{"key":"2021113010064600900_B12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2337\/diabetes.55.02.06.db05-1041","article-title":"Hemostatic markers of endothelial dysfunction and risk of incident type\u00a02 diabetes: the Framingham Offspring Study","volume":"55","author":"Meigs","year":"2006","journal-title":"Diabetes"},{"key":"2021113010064600900_B13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ahj.2006.10.014","article-title":"Asymmetric dimethylarginine, cortisol\/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?","volume":"153","author":"Anderson","year":"2007","journal-title":"Am. Heart J."},{"key":"2021113010064600900_B14","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(01)07184-7","article-title":"Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine","volume":"358","author":"Valkonen","year":"2001","journal-title":"Lancet."},{"key":"2021113010064600900_B15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/hrt.80.4.334","article-title":"von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction","volume":"80","author":"Jansson","year":"1998","journal-title":"Heart"},{"key":"2021113010064600900_B16","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1161\/01.CIR.98.21.2241","article-title":"High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor","volume":"98","author":"Thogersen","year":"1998","journal-title":"Circulation"},{"key":"2021113010064600900_B17","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1471-0528.2006.01090.x","article-title":"Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome","volume":"113","author":"Brinkworth","year":"2006","journal-title":"BJOG"},{"key":"2021113010064600900_B18","first-page":"1851","article-title":"Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome","volume":"85","author":"Mather","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B19","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.atherosclerosis.2007.03.002","article-title":"The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome","volume":"196","author":"Charitidou","year":"2008","journal-title":"Atherosclerosis"},{"key":"2021113010064600900_B20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.thromres.2004.11.026","article-title":"Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome","volume":"116","author":"Carmassi","year":"2005","journal-title":"Thrombosis Research"},{"key":"2021113010064600900_B21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1530\/eje.0.1500793","article-title":"The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels","volume":"150","author":"Diamanti-Kandarakis","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"2021113010064600900_B22","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/jcem.87.7.8634","article-title":"A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome","volume":"87","author":"Kelly","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2265.2007.02849.x","article-title":"Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome","volume":"67","author":"Demirel","year":"2007","journal-title":"Clin. Endocrinol."},{"key":"2021113010064600900_B24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/dc06-0618","article-title":"Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome","volume":"30","author":"Meyer","year":"2007","journal-title":"Diabetes Care"},{"key":"2021113010064600900_B25","first-page":"377","article-title":"Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic Ovary Syndrome","volume-title":"Current Issues in Endocrinology and Metabolism","author":"Zawdaki","year":"1992"},{"key":"2021113010064600900_B26","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1210\/jc.2004-1428","article-title":"Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women","volume":"90","author":"Teede","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"2021113010064600900_B28","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0002-9149(01)02063-X","article-title":"Plasma concentrations of asymmetric dimethylarginine are increased in patients with type\u00a02 diabetes mellitus","volume":"88","author":"Abbasi","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"2021113010064600900_B29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0002-9343(01)00948-2","article-title":"Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome","volume":"111","author":"Legro","year":"2001","journal-title":"Am. J. Med."},{"key":"2021113010064600900_B30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1210\/jc.2007-0842","article-title":"Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment","volume":"93","author":"Heutling","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1472-6483(10)61634-3","article-title":"Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?","volume":"9","author":"Orio","year":"2004","journal-title":"Reprod. Biomed. Online"},{"key":"2021113010064600900_B32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/gye.17.3.231.237","article-title":"Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system","volume":"17","author":"Sills","year":"2003","journal-title":"Gynecolog. Endocrinol."},{"key":"2021113010064600900_B33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.metabol.2006.11.003","article-title":"Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia","volume":"56","author":"Eid","year":"2007","journal-title":"Metab. Clin. Exp."},{"key":"2021113010064600900_B34","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.2337\/diabetes.50.7.1522","article-title":"Transcriptional regulation of plasminogen activator inhibitor type\u00a01 gene by insulin: insights into the signaling pathway","volume":"50","author":"Banfi","year":"2001","journal-title":"Diabetes"},{"key":"2021113010064600900_B35","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1139\/O07-011","article-title":"Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type\u00a01 release in endothelial cells","volume":"85","author":"Jin","year":"2007","journal-title":"Biochem. Cell Biol."},{"key":"2021113010064600900_B36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2265.1998.00525.x","article-title":"The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women","volume":"49","author":"Buckler","year":"1998","journal-title":"Clin. Endocrinol."},{"key":"2021113010064600900_B37","doi-asserted-by":"crossref","first-page":"860","DOI":"10.2337\/diab.46.5.860","article-title":"Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease","volume":"46","author":"Alessi","year":"1997","journal-title":"Diabetes"},{"key":"2021113010064600900_B38","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1161\/01.CIR.99.24.3092","article-title":"Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase","volume":"99","author":"Ito","year":"1999","journal-title":"Circulation"},{"key":"2021113010064600900_B39","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1161\/01.CIR.0000091083.61609.DF","article-title":"Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine","volume":"108","author":"Holden","year":"2003","journal-title":"Circulation"},{"key":"2021113010064600900_B40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.metabol.2005.09.008","article-title":"Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome","volume":"55","author":"Glueck","year":"2006","journal-title":"Metab: Clin. Exp."},{"key":"2021113010064600900_B41","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2265.2008.03247.x","article-title":"Increased serum advanced glycation end products is a distinct finding in lean women with PCOS","volume":"69","author":"Diamanti-Kandarakis","year":"2008","journal-title":"Clin. Endocrinol."},{"key":"2021113010064600900_B42","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc06-0531","article-title":"Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type\u00a02 diabetes","volume":"29","author":"Stirban","year":"2006","journal-title":"Diabetes Care"},{"key":"2021113010064600900_B43","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2021113010064600900_B44","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/jcem.87.2.8199","article-title":"Altered vascular function in young women with polycystic ovary syndrome","volume":"87","author":"Kelly","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B45","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1210\/jcem.86.11.7880","article-title":"Repeatability characteristics of simple indices of insulin resistance: implications for research applications","volume":"86","author":"Mather","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B46","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1210\/jc.2003-031205","article-title":"Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome","volume":"89","author":"Diamanti-Kandarakis","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B47","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1210\/jcem.86.11.8013","article-title":"Variations in endothelial function and arterial compliance during the menstrual cycle","volume":"86","author":"Williams","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0188-0128(98)00008-6","article-title":"Changes in insulin sensitivity, secretion and glucose effectiveness during menstrual cycle","volume":"30","author":"Escalante\u00a0Pulido","year":"1999","journal-title":"Arch. Med. Res."},{"key":"2021113010064600900_B49","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1210\/jc.2004-0598","article-title":"Dynamic variability of hemostatic and fibrinolytic factors in young women","volume":"89","author":"Giardina","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010064600900_B50","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1210\/jc.2005-0231","article-title":"Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women","volume":"90","author":"Blum","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/116\/10\/761\/439479\/cs1160761.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/116\/10\/761\/439479\/cs1160761.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T10:07:29Z","timestamp":1638266849000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/116\/10\/761\/68485\/A-comprehensive-assessment-of-endothelial-function"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,5,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20080218","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,15]]}}}